Importantly, despite the modest effects on performance by pharmacologically blocking CARM1, our results indicate that investigations into the use of CARM1 inhibition as a treatment for cancer (19–22, 49–51) and its related sequelae (e.g., cachectic muscle wasting) should continue. Here, CARM1 is linked to cancer.